AVROBIO, Inc. announced the appointment of Kim Raineri, as chief manufacturing and technology officer. He brings deep global experience in the cell and gene therapy industry, with a distinguished track record of innovation and implementation of Good Manufacturing Practices (GMP). AVROBIO’s founding chief manufacturing and technology officer, Kim Warren, Ph.D., will be retiring at the end of July. Among many other accomplishments, she led the development of plato®, the company’s proprietary gene therapy platform designed to bring gene therapy to patients worldwide through an efficient, automated, closed manufacturing system developed to be rapidly deployed to contracted manufacturing sites. Raineri has broad, global experience in GMP operations, including in the cell and gene therapy, biologics and medical device spaces. Prior to joining AVROBIO, he served as the vice president of operations for Nikon CeLL innovation Co., Ltd, a Japanese contract development and manufacturing organization. During his tenure, he established the company as the preferred provider of custom process development and manufacturing services for cell and gene therapy products in the Japanese market. Previously, Raineri held management positions at Lonza, serving as the business director for the cell therapy contract manufacturing operations in Singapore for five years, and prior to that as director of operations at Lonza’s Maryland facilities. Raineri was also previously the senior manager of the Tissue Processing Lab at CryoLife Inc.
Tectonic Therapeutic, Inc. is a biotechnology company. The Company is focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs). Leveraging its technology platform called GEODe (GPCRs Engineered for Optimal Discovery), the Company is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery and harness the human body to modify the course of disease. The Companyâs lead program, TX000045 (TX45), is an Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone relaxin. TX45 is being evaluated in Phase Ia/Ib clinical trials as a potential treatment for Group 2 Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (HFpEF). Its second program addresses Hereditary Hemorrhagic Telangiectasia (HHT).